SPORE in Lymphoma

罗切斯特大学詹姆斯·P·威尔莫特癌症中心(JPWCC)和亚利桑那大学亚利桑那癌症中心(ACC)的这一淋巴瘤孢子应用程序提供了一个基础广泛的转化性研究计划，研究淋巴瘤生物学中几个尚未解决的主要问题。具体地说，这些项目将侧重于几种正在开发或已批准用于治疗三种最常见的非霍奇金淋巴瘤的新型、有针对性的治疗药物，即弥漫性大B细胞淋巴瘤、滤泡性淋巴瘤和套细胞淋巴瘤。我们首先将在体外和精心开发的模型系统中阐明作用和/或耐药性的机制；然后将设计和进行试验性临床试验，重点是相关研究，以验证这些机制。JPWCC和ACC的调查人员是两个项目的长期合作者，领导着每个项目。西南肿瘤组淋巴瘤委员会的临床和病理资源也被整合到这个项目中。项目包括： 研究项目1：侵袭性B细胞性非霍奇金淋巴瘤靶向Aurora Kinase， 项目2：优化氧化还原调节作为非霍奇金淋巴瘤的治疗策略。 项目3：增强非霍奇金淋巴瘤的蛋白酶体抑制活性。 项目4：淋巴瘤激发细胞的特征。

This Lymphoma SPORE application from the James P. Wilmot Cancer Center (JPWCC), University of Rochester, and the Arizona Cancer Center (ACC), University of Arizona provides a broad based, translational research program studying several major unresolved issues in the lymphoma biology. Specifically the projects will focus on several novel, targeted therapeutic agents either in development or approved for the treatment of three of the most common non-Hodgkin's lymphomas, namely diffuse large B-cell, follicular and mantle cell lymphoma. We will initially seek to elucidate mechanisms of action and/or resistance both in vitro, and in carefully developed model systems; then pilot clinical trials with an emphasis on correlative studies will be designed and conducted to validate these mechanisms. Investigators at the JPWCC and the ACC, long-time collaborators, lead each of the programs. The clinical and pathologic resources of the Lymphoma Committee of the Southwest Oncology Group are also integrated into this program. Projects include: Research Project 1: Targeting Aurora Kinase in Aggressive B-cell non-Hodgkin's Lymphoma, Project 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL. Project 3: Potentiating Proteasome Inhibitor Activity in NHL. Project 4: Characterization of Lymphoma-lnitiating Cells.